Lentigo maligna has an extensive and neoplastic character. It typically progresses slowly and may eventually develop into an invasive melanoma, which is called lentigo maligna melanoma. Ocular melanoma is the second most common type of melanoma. The uvea is the most common site of origin of ocular melanomas, while conjunctival melanoma accounts for about 1-5% of cases. In this article, we describe a rare case of synchronic conjunctival melanoma and lentigo maligna on the face.
INTRODUCTION
In 1892, Hutchinson described a form of melanoma in situ that affected sun-exposed areas in the elderly and named it "senile freckles". Later, Dubreuilh coined the term lentigo maligna (LM), and demonstrated the extensive and neoplastic nature of the lesion.
It typically progresses slowly and may eventually develop into an invasive melanoma, which is called lentigo maligna melanoma. Ocular melanoma is the second most common type of melanoma. The uvea is the most common site of origin of ocular melanomas, comprising more than 80% of cases, while conjunctival melanoma accounts for about 1-5% of cases. Although most ocular melanomas are primary, cutaneous melanoma metastases may also occur in the ocular region, which represent less than 5% of all metastases to the eye and orbits. Conjunctival melanoma typically presents as a raised pigmented lesion, although sometimes it may be amelanotic, surrounded by prominent blood vessels or areas of primary acquired melanosis (PAM). It can appear in any conjunctival region including the bulbar conjunctiva, the eyelid, the fornices, semilunar fold, and caruncles. In most cases, the lesion develops at the limbus. Complaints about the sudden appearance of a local pigmented lesion is common, while irritation and pain are rare events. [3] [4] [5] The mainstay treatment of conjunctival melanoma is tumor resection with wide surgical margin. In most cases, adjunct therapy is associated with cryotherapy. Some authors recommend the use of additional brachytherapy. Orbital exenteration is reserved for cases in very advanced stages. Local tumor recurrence has been reported in 60% of patients. Metastases occur most commonly to the preauricular and submandibular lymph nodes. Mortality rate in 10 years is between 23% and 30%. 4, 6 
